The US Food and Drug Administration announced on Friday that it has granted full approval to Pfizer and BioNTech’s COVID-19 vaccine for adolescents aged 12 to 15, Reuters reports.
The vaccine, sold under the brand name Comirnaty for adults, was available with an emergency license from May 2021 for the 12-15 age group. It will now be sold under the same brand name for teenagers as well.
The FDA said Friday that the full approval follows a rigorous analysis and evaluation of safety and efficacy data. The vaccine was approved for use in people aged 16 and over last August.
About 67% of the total US population has been fully vaccinated against COVID-19, according to federal data.
The FDA last month asked vaccine makers, including Pfizer and rival Moderna Inc MRNA.O, to change the design of their booster vaccines starting in the fall to include ingredients tailored to fight the currently prevalent subtypes Omicron BA.4 and BA.5 of the coronavirus.
Source: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
